Фактор риска
Очень высокая волатильность
Фактор доходности
Очень низкие или нет дивидендов
О компании
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
Оценка компании
Как с исторической, так и с прогнозной точек зрения акции справедливо оценены по сравнению с аналогичными акциями.